|Number of samples:||10|
|Release date:||Mar 3 2015|
|Last update date:||Dec 9 2016|
|Diseases:||Tumor Lysis Syndrome|
|Dataset link||Direct but No Transgenerational Effects of Decitabine and Vorinostat on Male Fertility|
We studied genome-wide DNA methylation changes in decitabine treated mice and their F3-generation. For this, we treated male C57BL/6 mice (seven weeks old) for seven weeks (intraperitoneal, three times per week) with the DNMT inhibitor decitabine (5-aza-2'-deoxycytidine, 0.1 µg/g, n = 17) or with vehicle (7.5 % dimethyl sulfoxide in phosphate buffered saline, n = 16). The dose of decitabine per treatment was chosen according to the clinical application regimens in humans and refer to previous mice studies using this drug (Kelly et al, 2003; Oakes et al, 2007). For the investigation of transgenerational effects, 10 treated and untreated male mice were mated with four untreated female C57BL/6 mice each. The offspring was considered as F1-generation. The F2- and F3-generations were obtained by an identical mating scheme. Thus, only the P-generation males were treated with decitabine or control vehicle, the F1-, F2- and F3-generations were not subjected to any treatment. During this study, all mice were housed at 24 °C on a 12-h light, 12-h dark cycle and provided with food and tap-water ad libitum.
Citations per year